A complete application in a minute
Tailored resume and cover letter, ready to send.
Zealand Pharma U.S., Inc. in Cambridge, MA, is seeking a Scientist, Formulation and Analytical Sciences to enable early drug discovery across proteins, peptides and bioconjugates with flexibility across oligonucleotides and small molecules.
The role sits in Zealand Pharma’s new Cambridge research center and emphasizes formulation, analytical QC and automation from the ground up. You will deliver assay-ready materials, use mass spectrometry and UHPLC-based methods, and work cross-functionally to
Does it excite you to build formulation, analytical QC and automation capabilities from the ground up in a brand-new Cambridge research center, and do you have experience with formulating and characterizing peptides, proteins or bioconjugates and with laboratory automation? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague. Your new position As Scientist, Formulation and Analytical Sciences, you will enable early drug discovery across diverse modalities, including proteins, peptides and bioconjugates, with flexibility across oligonucleotides and small molecules. You will make sure the right molecules reach the right studies, in the right formulation and format, backed by the right analytical data. The position sits at the inception of Zealand Pharma’s new research center in Cambridge, Massachusetts, offering the chance to shape modern formulation, analytical QC and automation capabilities as the team scales. GxP experience is not required.
You are fanatical about quality and passionate about using automation to improve speed and reduce tedium. You combine formulation science, analytical chemistry and automation in equal measure, and you bring sound scientific judgment, accountability and a collaborative mindset. You thrive in a fast‑paced, emerging team, work independently and cross‑functionally, and communicate data and results clearly across scientific disciplines.
You will join Molecular Platform Development, a new organization within Zealand Pharma’s Cambridge, Massachusetts research center, established to strengthen and advance diverse drug modality capabilities in metabolic disease. The center is a collaborative, multidisciplinary discovery hub spanning early discovery through pre‑clinical development, closely connected to the Greater Boston life sciences ecosystem. [TBD: team size and reporting line]
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late‑stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts. Learn more at www.zealandpharma.com. Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long‑standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high‑profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co‑development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.